Discover how Chroma is expanding our impact.

Boston, MA, May 18, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced in vivo data that demonstrate 99% silencing of two distinct targets and compelling proof-of-concept for its epigenetic editing platform. The data presented at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting showcase the rapid advancement of the company’s programs and platform. The work describes the development of Chroma’s epigenetic editor targeting PCSK9, a well-characterized genetic target for addressing hyperlipidemia. The company’s epigenetic editor showed highly effective, durable, and specific silencing of PCSK9 in a transgenic…

Boston, MA, May 2, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced two oral data presentations that showcase the potential of its epigenetic editing platform at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, held May 16-20, 2023 in Los Angeles, California. The presentations include the first in vivo proof-of-concept data for Chroma’s epigenetic editing platform along with data demonstrating the key advantages of epigenetic editing for multiplex gene regulation. Chroma plans to release data from additional pipeline programs at upcoming scientific conferences.   “These data showcase…

Boston, MA, March 1, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the completion of a $135 million Series B financing led by GV (Google Ventures), with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management. The financing will support advancement of Chroma’s therapeutic programs toward the clinic, and continued investment in the…

Cambridge, MA, October 4, 2022 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the addition of Jeff Marrazzo, co-founder and former founding CEO of Spark Therapeutics, to its Board of Directors. “Jeff’s leadership at Spark yielded the first-ever approved gene therapy, and we are thrilled to bring his expertise to the Chroma Board,” said Catherine Stehman-Breen, M.D., CEO of Chroma. “He is a proven company builder who has successfully led the advancement of novel genomic medicines to patients. His unique perspective as a gene therapy pioneer will be instrumental as we reimagine…